Introduction Executive Summary Soft Tissue Sarcoma: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Soft Tissue Sarcoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends Soft Tissue Sarcoma Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Fibromun: Philogen • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis GPX-150: Monopar Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis PTC596: PTC Therapeutics • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Preclinical/Discovery Stage Products • Comparative Analysis HSB-114: Hillstream BioPharma • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Soft Tissue Sarcoma Key Companies Soft Tissue Sarcoma Key Products Soft Tissue Sarcoma- Unmet Needs Soft Tissue Sarcoma- Market Drivers and Barriers Soft Tissue Sarcoma- Future Perspectives and Conclusion Soft Tissue Sarcoma Analyst Views Soft Tissue Sarcoma Key Companies Appendix

Table 1 Total Products for Soft Tissue Sarcoma Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Advenchen Laboratories • Philogen • Gradalis • Epizyme • Eli Lilly and Company • Chugai Pharma France • CytRx • Arog Pharmaceuticals • Taiho Pharmaceutical • NantCell • Nanobiotix • KaryoPharm Therapeutics • Apexigen • Monopar Therapeutics • Lytix Biopharma • Novartis • Athenex • Bristol Myers Squibb • Merck sharp & Dohme Corp. • Incyte Corporation • Daiichi Sankyo • AstraZeneca • Pfizer • NantPharma • Iovance Biotherapeutics • Agenus • GlaxoSmithKline • AVEO Pharmaceuticals • Amgen • Atara Biotherapeutics • Bayer • VasGene Therapeutics • Mirati Therapeutics • EMD Serono • Novartis • Adaptimmune • PTC Therapeutics • Hillstream BioPharma • MedImmune • AstraZeneca